Abstract | BACKGROUND: METHODS: All observational studies and placebo-controlled or -uncontrolled randomized trials (RCTs) comparing the effect of TRT on different bone parameters were considered. RESULTS: Out of 349 articles, 36 were considered, including 3103 individuals with a mean trial duration of 66.6 weeks. TRT improves areal bone mineral density (aBMD) at the spine and femoral neck levels in observational studies, whereas placebo-controlled RTCs showed a positive effect of TRT only at lumber spine and when trials included only hypogonadal patients at baseline (total testosterone < 12 nM). The effects on aBMD were more evident in subjects with lower T levels at baseline and increased as a function of trial duration and a higher prevalence of diabetic subjects. Either T or estradiol increase at endpoint contributed to aBMD improvement. TRT was associated with a significant reduction of bone resorption markers in observational but not in controlled studies. CONCLUSION: TRT is able to inhibit bone resorption and increase bone mass, particularly at the lumbar spine level and when the duration is long enough to allow the anabolic effect of T and estrogens on bone metabolism to take place.
|
Authors | G Corona, W Vena, A Pizzocaro, V A Giagulli, D Francomano, G Rastrelli, G Mazziotti, A Aversa, A M Isidori, R Pivonello, L Vignozzi, E Mannucci, M Maggi, A Ferlin |
Journal | Journal of endocrinological investigation
(J Endocrinol Invest)
Vol. 45
Issue 5
Pg. 911-926
(May 2022)
ISSN: 1720-8386 [Electronic] Italy |
PMID | 35041193
(Publication Type: Journal Article, Meta-Analysis, Review, Systematic Review)
|
Copyright | © 2022. Italian Society of Endocrinology (SIE). |
Chemical References |
|
Topics |
- Bone Density
- Bone Resorption
(complications)
- Dietary Supplements
- Femur Neck
- Hormone Replacement Therapy
- Humans
- Hypogonadism
(drug therapy)
- Lumbar Vertebrae
- Testosterone
(pharmacology, therapeutic use)
|